CrystalGenomics Obtains Australian Patent for Blood Cancer Treatment

[Asia Economy Reporter Oh Ju-yeon] CrystalGenomics announced on the 21st that it has obtained the Australian patent for CG-806, a world-first (first in class) FLT3-BTK multi-inhibitor blood cancer drug candidate. The company secured broad patents covering substances including CG-806, manufacturing methods, compositions, and uses.

Most lymphomas are cancers caused by overexpression and genetic mutations of BTK, which regulates B-cell receptors, while FLT3 is a blood cancer occurring in about 35% of leukemia patients due to genetic mutations and overexpression.

Blood cancers develop resistance and the effectiveness of anticancer treatments sharply decreases when single molecular targeted therapies currently in use are repeatedly administered.

In contrast, CG-806 selectively inhibits only the signaling target protein clusters that cause BTK- and FLT3-related cancers, with the advantage of not inhibiting targets that cause side effects.

In June last year, CG-806 received FDA approval for Phase 1 clinical trials, and patient enrollment is underway at 23 hospitals across the United States.

The safety and tolerability of the drug are being evaluated in 130 patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and non-Hodgkin lymphoma.

Additionally, in July, the FDA granted further approval for a Phase 1 clinical trial targeting patients with acute myeloid leukemia (AML).

So far, CG-806 has shown remarkably excellent efficacy, according to Aptose Therapeutics in the U.S., which is conducting the clinical trials.

In particular, CG-806 demonstrates outstanding anticancer activity against resistant strains arising during treatment with ibrutinib and improved drug candidates, which generated approximately 5 trillion KRW in sales last year in lymphoma. It is also predicted to become a groundbreaking world-first (first in class) therapeutic for acute myeloid leukemia, and the company expects it to be a game-changer in the blood cancer treatment market upon successful clinical trials.

A CrystalGenomics official stated, "Aptose Therapeutics in the U.S. is fully committed to prioritizing the development of CG-806 over their other drug candidates," adding, "The Aptose development team, composed of former Novartis Gleevec developers, plans to include technology transfer after completing Phase 2."

An Aptose representative in the U.S. said, "CG-806 currently shows excellent tolerability and pharmacological activity," and added, "It not only inhibits kinases that cause various tumors but also demonstrated an effect of increasing lymphocytes in peripheral blood."

This content was produced with the assistance of AI translation services.